Compared with other cutaneous melanomas, this lower mutation burden in ALM and mucosal melanomas11, 14 could potentially explain their poor response to anti‐programmed cell death protein 1 (anti‐PD‐1) therapy.15 Here, PDCD1 is linked to acral lentiginous melanoma.